All In Biotech

Drug Trial Radar · NCT00694369

A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)

A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain

Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

588

Actual

Start

Jun 2008

Primary completion

Dec 2008

Study completion Jan 2009

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jun 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pain relieving effect of different doses of MK0663 with placebo and other pain relievers/analgesics in patients with postoperative dental pain. Pain intensity and relief will be measured by the total pain relief score (TOPAR) and patient evaluation.

Conditions

  • Postoperative Dental Pain

Interventions

  • Comparator: etoricoxibDrug

    etoricoxib 90 mg; 120 mg (once daily) over three days.

  • Comparator: ibuprofenDrug

    ibuprofen 2400 mg (600 mg Q6h) over three Days

  • Comparator: acetaminophen + codeineDrug

    acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days

  • Comparator: placeboDrug

    matching placebo over three Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)Time frame: Over the first 6 hours post the initial Day 1 dose of the study medication

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.